With the rapidly developing use of Next Generation Sequencing (NGS) technologies, there has been a surge in our knowledge of the genomic landscape of prostate cancer and a movement towards developing a molecular sub-classification system for the disease. With this new understanding comes enormous clinical potential, both for the development of biomarkers and new therapeutic targets. Herein, we highlight the potential clinical utility of recent discoveries and how they fit in to our current paradigm. We describe the challenges that lie ahead as we move genomic sequencing towards routine clinical practice and adopt precision cancer care for prostate cancer patients.
展开▼
